{"title":"Morphology of the endocrine pancreas in cyclosporine-treated glucose-intolerant Wistar rats.","authors":"S Lucke, E Radloff, R Laube, H J Hahn","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The toxic effect of Cyclosporin A (CS-A) (1.25-50.0 mg/kg body weight) on the endocrine pancreas of Wistar rats was morphologically investigated. The treatment of animals with CS-A doses above 5 mg/kg for 2 weeks resulted in a disturbed glucose tolerance, a reduced B-cell volume density and degranulation, vacuolization and decreased mitotic activity of the B-cells. After withdrawal of the drug the impaired parameters were stepwise normalized, starting with regranulation of pancreatic B-cells, followed by a stimulation of mitotic activity, and increase of B-cell volume density. When continuing the CS-A treatment with doses lower than 5.0 mg/kg for longer periods we observed a decreased body weight gain and reduced pancreatic insulin content.</p>","PeriodicalId":72195,"journal":{"name":"Anatomischer Anzeiger","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anatomischer Anzeiger","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The toxic effect of Cyclosporin A (CS-A) (1.25-50.0 mg/kg body weight) on the endocrine pancreas of Wistar rats was morphologically investigated. The treatment of animals with CS-A doses above 5 mg/kg for 2 weeks resulted in a disturbed glucose tolerance, a reduced B-cell volume density and degranulation, vacuolization and decreased mitotic activity of the B-cells. After withdrawal of the drug the impaired parameters were stepwise normalized, starting with regranulation of pancreatic B-cells, followed by a stimulation of mitotic activity, and increase of B-cell volume density. When continuing the CS-A treatment with doses lower than 5.0 mg/kg for longer periods we observed a decreased body weight gain and reduced pancreatic insulin content.